. Glynn Wilson the Chairman and CEO
of TapImmune will present at the Sachs Associates' 3rd Annual Bio Partnering & Investment Forum on 2/23. The company had Phase I trials completed with 20 of 21 cancer patients reacting with positive immune responses. Additionally, TapImmune has a very deep drug pipeline in multipe indications for upcoming Phase II trials. Increased awareness of excellent results should promote further investment confidence and result in increases on the stock chart. We already see this happening right now.